Hemophilia A is caused by a deficiency of factor-Vlll procoagulant (NIII) activity. The current treatment by frequent infusions of plasma-derived Nlll concentrates is very effective but has the risk of transmittance of blood-borne viruses (human immunodeficiency virus IHIVI, hepatitis viruses). Use of recombinant DNA-derived Nlll as well as gene therapy could make hemophilia treatment independent of blood-derived products. So far, the problematic production of the Nlll protein and the low titers of the Nlll retrovirus stocks have prevented preclinical trials of gene therapy for hemophilia A in large-animal models. We have initiated a study of the mechanisms that oppose efficient Nlll synthesis. We have established that Nlll cDNA contains sequences that EMOPHILIA A is a bleeding disorder that affects approximately 8.5 in 100,OOO humans and is caused by a deficiency of functional blood coagulation factor VnI (fVII1). For those afflicted, hemophilia is potentially lifethreatening and crippling. Hemophilia A is treated by regular infusions (prophylactic or on-demand) with fVIII-enriched concentrates derived from human plasma. This protein-replacement therapy has been very effective and has resulted in a dramatic increase in both the life expectancy and the quality of life.' Nonetheless, even the treated patient is prone to spontaneous hemorrhages with the associated risk of chronic joint damage. In addition, therapy with plasma-derived NI11 has resulted in transmission of several human viruses, such as human immunodeficiency virus (HIV) and hepatitis virus. The ideal therapy, therefore, would be independent of blood-derived products? The recent admission of recombinant DNA-derived fVIII for treatment of hemophilia A3 is a major step in that direction, although its extensive use is still problematic due to its high cost, which results from the difficult production of this p r o d~c t .~ Somatic gene therapy, therefore, is deemed to be a welcome alternative for hemophilia Implantation of autologous cells, genetically modified to produce fVIII, would allow a continuous production of fVIII in the patient, thereby preventing the spontaneous bleeding episodes.
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Somatic gene therapy for hemophilia A is not necessarily restricted to the cells that normally produce fVIII. Research has been directed at genetic modification of cells from tissue types that are more amenable to manipulation, such as the ~k i n ,~.~ endothelium, bone marrow: and muscle." To date, retrovirus-mediated gene transfer is the most tested system in clinical trials of gene therapy.6," To accommodate factor VI11 cDNA into the retroviral vectors, we and others have used shortened cDNA clones from which the region encoding the nonessential internal B-domain has been deleted.7~8~'2 Such vectors have been successfully used to produce functional fVIII in primary human cell^.^.^ However, the relatively low titer of fVIII retroviruses and the disappointingly low protein yields have hampered the initiation of preclinical trials in large-animal models. Several mechanisms have been identified that thwart the production of fVIII. Accumulation of fVIII mRNA is inhibited, purportedly as the result of some posttranscriptional event,8.13 the intracellular transport of W111 is very inefficient,4'I4 and, once secreted, the protein is extremely susceptible to proteolytic degradation and needs to be stabilized by the von Willebrand factor (vWF) ~r o t e i n .~
We report evidence for the presence of a dominant transcriptional silencer element in the fVIII cDNA and map the fVIII cDNA sequences involved. Characterization of this element will aid the development of more efficiently expressed fVIII cDNA clones. Increased expression would not only advance the development of gene therapy protocols but could also increase yields of recombinant-DNAderived fVIII and, thus, will reduce the currently high price of this product.
MATERIALS AND METHODS

Cell lines and virus preparation.
Cell lines were grown in highglucose (4.5 g/L) Dulbecco's modified Eagle's medium supplemented with 8% fetal calf serum in a 5% CO2 atmosphere at 37°C. Generation of virus-producing cell lines and retrovirus harvesting, infection, and titration were performed as described? Polyclonal cell lines containing a single copy of the provirus were generated by infection of near-confluent cell cultures with a low multiplicity of infection (moi; <0.01) and selection in 400 pg G418 per milliliter. The resulting G418R polyclonal cell populations were maintained in medium containing 200 pg G418 per milliliter until use. In all RNA analyses. Total cellular RNA was isolated from near-confluent cell cultures by the LiCI-urea method,I7 and Northern blotting analyses were performed on nitrocellulose. To study the stability of the mRNA, actinomycin D (ActD; Sigma, St Louis, MO) was added to near-confluent cultures at zero time to a final concentration of 5 pg/mL. RNA was isolated at the desired timepoints and analyzed by Northern analysis.
Probes. The neoR-specific probe used for the Northern analysis was the 1.3-kb HindIII-Sma I fragment of pRSVneo." The NIII-specific probe was the 4.8-kb
Sul I-Sal I fragment from pUC-F8dB2.6.' The glyceraldehyde-3-phosphate (GAPDH)-specific probe was the 1.3-kb Pst I fragment from plasmid pRGAPDH-13," representing the entire rat cDNA. The c-myc-specific probe used was the 1.3-kb Cla I-EcoRI fragment of the human c-myc gene."' Probes were radiolabeled with [~t-~~P]deoxycytidine triphosphate (dCTP) with the use of random hexanucleotide primers and Klenow Escherichia coli DNA polymerase I (Pollk). To obtain singlestranded probes for the nuclear run-on analysis, the neoR and GAPDH fragments were cloned into M13mp18 and MI3mp19. A single-stranded NIII-specific probe was constructed by insertion the 658-bp HindIIt fragment, encoding part of the AI domain, into phage M13mp18 DNA.
CAT plasmids and assays. Plasmid DNA ( I O pg) was transfected into near-confluent cultures of HeLa cells with the calcium-phosphate precipitation procedure in a 9-cm tissue-culture dish. At 40 hours after transfection, the cells were lysed, and SO pg of protein lysate was used for the CAT activity assays.lh Plasmid pMuLV-CAT was used to assess the effect of the fVIII cDNA fragments on the expression of the marker (CAT) gene. Plasmid pMuLV-CAT contains the enhancer and promoter from the Moloney murine leukemia virus (MO-MuLV) LTR to drive the CAT gene.'" The NI11 cDNA fragments were inserted into the unique Hpa I site, 34 and 63 bp 5' of the two tandem SV40 polyadenylation signals, derived from the late transcription unit. Unless stated otherwise, O S pg of plasmid pMuLV-CAT or equimolar amounts of the clones canying fVIII cDNA fragments were used in the transfection experiments. The amount of plasmid DNA was adjusted to 10 pg per dish with plasmid pUC18 DNA. In the Hpa I site of plasmid pMuLV-CAT, the following fragments (see Fig S) to 1869), and AHWBm (Acc I-Bgl 11, 1033 to 1680 fused to BarrzHtHindIIt, 1869 to 2277). All sites mentioned are present in the tVItI cDNA, except the Sal I sites, which flank the F8dB2.6 cDNA, and the Xhn I site, which has been created at the junctions of the Bdomain deletion. All fragments were isolated from plasmid pUCF8dB2.6.7
Factor V/// und /X us.suys. Human fVIlI in tissue-culture medium was quantitated via an enzyme-linked immunosorbent assay (ELISA), as described previ~usly.~ Human AX was determined by ELISA as described.*' In all assays, appropriate dilutions of pooled normal human plasma were used as references. The concentrations of N I 1 1 and flX in the pools were assumed to be 100 ng/mL and 3 pg/mL, respectively.
Nucleur run-on assays. Nuclei were isolated from polyclonal cell cultures by NP40 lysis as described" and stored at -80°C in a solution containing 50 mmol/L Tris-HCI (pH 8. . Aliquots were counted, and identical amounts of radiolabeled RNA were added to each probe filter and hybridized for 48 hours at 42°C. The probe filterh were prepared by spotting 2 pg of the single-stranded phage-M I3 clones onto 0.22-pm nitrocellulose membranes. After the hybridization, the filters were washed in 2X standard sodium citrate (SSC), 0.5% SDS at 50°C and subsequently incubated in I O mmol/L Tris-HCL (pH 7.6), 300 mmolL NaCI, and I O pg/mL RNase A (DNasefree): washed in 2x SSC. 0.1% SDS at 42°C; and left to expose Kodak XAR-S films (Eastman-Kodak, Rochester, NY ).
RESULTS
The W111 protein consists of three types of structural domains that are arranged in the order Al:A2:B:A3:Cl:C2. The unique B domain delimited by amino acids 740 and 1648 is removed during the proteolytic processing and activation and is dispensable for coagulation activity in vivo and in vitro."." To accommodate the NI11 cDNA into a retroviral vector without exceeding the packaging capacity of the vector, we used a NI11 cDNA from which we had deleted virtually all codons for the B domain. We have previously shown that the resulting B domain-deleted NI11 is fully f~nctional.~ The vector used relies on differential splicing for the expression of the NI11 cDNA and the neoR gene (Fig IA) . The titers of the NI11 vectors ( 5 3 X IO' G418R colony-forming units [CFU]/mL) are much lower than those routinely obtained with other vectors ( IO5 to l O6 CFU/mL), as is the amount of NI11 protein secreted. For example, the amount of NI11 protein is at least 200-fold lower on a molar basis than that of coagulation factor IX from cells infected with a retroviral vector carrying fIX cDNA ( Repression of expression by NI11 cDNA fragments. (A) In the retroviral vector IM5F8dB2.6') used in this study, transcription is driven by the myeloproliferative sarcoma virus LTR. The unspliced mRNA, from which the B-domain-deleted NI11 can be translated, and the spliced messenger, from which the neon is derived, are indicated: SA and SD, the splice-donor and acceptor sites, respectively; AAA, the polylA)-tail of the transcripts. (B) Northern blot analysis of the G418R Rat2 cell cultures after infection with the retroviral vectors M5neo (lane l), M5F8dB2.6 (lanes 2 and 41, and XT-HER (lane 3). At 24 hours before RNA isolation, the cells were fed fresh medium (lanes 1 through 3) or fresh medium with 6 mmol/L sodium butyrate (lane 4). RNA (20 p g ) was electrophoresed on a formaldehyde-agarose gel and blotted onto a nitrocellulose membrane. Hybridization was performed with a neon-and a GAPDH-specific probe, as indicated. both the low virus production by the packaging cells and the low amounts of N I 1 1 protein secreted by the fVlII virusinfected cells. A Northern analysis of a G41SR population of Rat2 fibroblasts that contain the M5F8dB2.6 vector confirmed a low abundance of vector-specific RNA compared with cells infected with the parental MSneo vector (Fig 1 B) , in which both the unspliced and spliced mRNAs are distinct. This is not due to the large size of the W111 cDNA insert, as is shown by the amounts of 8.3-to 7.8-kb EGF-r mRNA in cells harboring a vector carrying the human EGF-r cDNA, which is similar in size to the B domain-deleted fVlII cDNA.
The absence of rearrangements in the M5F8dB2. Factor VI11 mRNA is stable in the packaging cells. TO study the stability of the N I 1 1 transcripts in the packaging cell line Psi2:M5F8dB2.6, transcription was blocked with ActD, an inhibitor of RNA polymerase 11. At various times, RNA was extracted from the cell cultures and analyzed by Northern blotting (Fig 2) . No significant decrease was observed up to 6 hours after addition of the ActD, suggesting that the W111 transcripts are rather stable in these cells. Rehybridization of this blot with a c-myc-specific probe showed the expected rapid decay of the c-myc transcripts [half-life (tin), approximately 15 minutes2'), confirming the effectivity of the ActD block. The amount of RNA loaded was verified by reprobing the blot with a GAPDH-specific probe, an mRNA known to have a long half-life.'' From these data we conclude that the steady-state W111 mRNA is stable (tin, 2 6 hours). The fact that not only accumulation of the unspliced messenger is inhibited in the MSF8dB2.6-infected cells, but also that of the spliced neoR messenger, which does not contain any fVIII, suggests. that repression acts before splicing occurs, possibly at the level of transcription. The W111 viruses produced by the Psi2: MSF8dB2.6 cell line have been used to generate the WIIIproducing rodent cell lines described here, thus excluding the possibility that the W111 vector in this cell line contains RNA-stabilizing mutations. 
Expression is repressed at the level qf transcription.
A nuclear run-on analysis was performed to measure the transcription rate of the integrated fVIII provirus in both G41gR Rat2:M5F8dB2.6 cells and G41gK Rat2:MSneo cells. As shown in Fig 3, the neoR probe detects a signal only in RNA isolated from the M5neo-infected cells. In the Rat2: M5F8dB2.6 cells, neither the neoK probe nor the NIII-specific probe shows any transcription of the provirus. The absence of signal with the antisense neo' probe confirms the specificity of the hybridization. The equality of labeling efficiencies was verified by a probe specific for the cellular GAPDH transcripts. Thus, insertion of the fVlll cDNA into the M5neo vector reduces the transcription of the integrated provirus to very low levels.
Factor VI11 cDNA fragments repress expression . f a heterologous gene. To study whether fVlll cDNA sequences can repress expression of a heterologous gene, f v l l l cDNA fragments were cloned in the pMuLV-CAT expression vector (see Fig 5) . In this vector, expression of the CAT reporter gene is driven by the MO-MuLV LTR.'" To maximally mimic the natural configuration of the repressor elements, the fVIII cDNA fragments were introduced into the unique Hpa I site of the expression plasmid. This site is located within the transcription unit but 3' of the CAT-encoding open reading frame so as not to influence translation of the CAT message. Two fragments were tested: SX, encompassing domains A1 and A2, and XS, which encodes domains A3, Cl, and C2 (see Fig 5) . Initially, both fragments were tested in the orientation they had in the retroviral vector. Insertion of the XS fragment did not cause a lower CAT activity than the parental pMuLV-CAT vector, whereas insertion of the SX fragment decreased CAT activity dramatically (Fig 4, left panel) . A similar decrease of CAT activity was observed when the SX fragment was tested in the reverse orientation. In stably transfected polyclonal cell cultures too, the SX fragments repressed expression of the MuLV-driven CAT-reporter gene (Fig 4, center panel) . Northern blot anal-HOEBEN ET AL ysis of RNA extracted from these cultures showed a vastly reduced amount of CAT mRNA in cells carrying the pMuLV-CAT/SX plasmid, which confirms that the decreased CAT activity in the SX fragment-containing cell population is reflecting the reduced amounts of CAT mRNA (data not shown). From these data we conclude that the repressor element that resides in the W111 cDNA inhibits the expression of integrated as well as unintegrated heterologous genes and that this repression is independent of the orientation of the f V I I l cDNA insert.
To map the sequences responsible for this repression in more detail, various subfragments have been tested for their capacity to reduce CAT activity (Fig S) . The AH fragment was a far more potent repressor than SA. The smallest fragment that could bring about repression was the PP fragment. Smaller fragments derived from the AH fragment, eg, HB, BH, XmB, and XmBm, did not decrease CAT activity. However, when the 305-bp XmB fragment, which by itself does not repress expression, was deleted from AH, the resulting clone AHdXmB was unable to repress expression. Deletion of the XmB fragment from the SX fragment, too, disrupted the repressor, as witnessed by the decreased CAT activity after transient expression (Fig 5) and in stably transfected polyclonal cell populations (Fig 4, center panel) . From these data, we conclude that sequences in the 305-bp XmB fragment are part of the repressor element, but are not sufficient to mediate repression.
The repression can be relieved by competitor DNA. In a competition experiment, the repression induced by the SX and the SXdXmB fragments were compared in the absence and in the presence of a 40-fold excess of the competitor plasmid, pUC-AH. The SX fragment represses expression I : : I M5neo M5F8dB2.6 Cells of these cultures, which contain approximately two copies of the reporter plasmid per cell (data not shown), were harvested, and protein lysates 110 pg) were analyzed for CAT activity as described in Materials and Methods. (Right panel) Repression can be relieved by cotransfection of excess amounts of Nlll cDNA. The reporter plasmid (0.2 pg) with either the SX (lanes 10 and 11) or the SXdXmB fragments (lanes 12 and 13) cloned in the Hpa l site were transfected in the presence of a 40-fold molar excess of either plasmid pUC18 DNA (lanes 10 and 12) or plasmid pUC-AH DNA, which carries the fvlll cDNA coding for the A2 domain (lanes 11 and 13) . CAT activity was determined in protein lysates of the transfected cells as described in Materials and Methods. Note that the experimental conditions used in the experiments shown in the three panels differ and do not permit comparison of the data.
of the CAT gene, in contrast to the SXdXmB construct (Fig  4, right panel) . However, although cotransfection of the pUC-AH construct does not increase the expression of the reporter gene with the SXdXmB fragment inserted, the SX fragment-induced repression was relieved, and the CAT level was similar to the SXdXmB fragment. These data indicate that the repression is not caused by intrinsic properties of the DNA (ie, an unfavorable conformation), but that the repression is mediated by a cellular factor (or factors) that can be titrated off.
DISCUSSION
This report describes the identification of sequences in the coding region of human N I 1 1 cDNA that repress expression at the level of transcription. This repressor downmodulates the expression of NI11 retroviral vectors, which results in inferior W111 protein synthesis and reduces the production of recombinant retroviruses by at least two orders of magnitude. The scarcity of the vector-specific mRNA in the packaging lines can fully explain the low titers of the W111 retroviral vectors. This is in agreement with the observation that amplification of the N I 1 1 vector in the packaging cell lines increases virus production." Furthermore, the amount of neo' transcripts in the target cells may be too low to allow the cell to survive selection by G418, lowering the apparent viral titer. Our observations confirm and extend the description by Lynch et alx of the inhibition of mRNA accumulation by W111 cDNA sequences [nucleotides (nt) 1681 to 2277, followed by 5002 to 55821. However, we found the repression to be dependent on the presence of the Xmrz I-&/ I1 fragment (nt 1375 to 1680), which is located outside the region identified by these investigators. The cause of this discrepancy is not clear. Whereas the above mentioned study relied on virus production as a parameter for repression, we exploited a more direct assay based on the transient expression of a CAT gene. thereby circumventing the problems with the instability (deletion of NI11 sequences') of the viral vectors.
Kaufman et all3 studied RNA levels in Chinese hamster ovary (CHO) cells containing multiple (>loo) W111 cDNA copies and vWF cDNA expression vectors and observed 40-fold lower amounts of Wlll RNA than of vWF RNA when corrected for expression vector copy number. The transcription rates of both genes were found to be similar in a nuclear run-on analysis, which suggested that the cause of repression was posttranscriptional.'3 In contrast, our study suggests the inhibition to be caused by a transcriptional mechanism. Our conclusion is based on several lines of evidence. First, the difference in steady-state amount of vector-specific RNA observed in cells infected with the MSneo vector and its MSF8dB2.6 derivative reflects the transcription rates as measured in a nuclear run-on assay. Second, the. subgenomic neo' RNA, which does not contain any N I 1 1 sequences, is repressed in cells containing the Wlll vector, suggesting a mechanism that operates before splicing occurs. Third, the relative stability of the W111 mRNA in the packaging lines excludes cytoplasmic stability as a mechanism. This is further supported by the observation that insertion of the SX the fragment that only moderately affected CAT activity (twofold t o threefold reduction; +/-l is represented by a shaded bar; and fragments that affected CAT activity hardly, if at all, (less than 50% reduction; -) are hatched. All fragments were tested in the same orientation they had in the retroviral vector. The inset shows the CAT-reporter plasmid ~M u L V -C A T~ used in this study. The Hpa I site was used t o insert the Wlll cDNA fragments; sd and sa, splicedonor and splice-acceptor sites, respectively; PA, polyadenylation signals.
fragment into the transcription unit of the CAT reporter does not change the stability of the transcript (tin, >2 hours in Rat2 cells; F.J.F., S.J.C., and R.C.H., unpublished data, February 1994). Also, the observation that treatment of the cells with sodium butyrate, a known stimulator of transcription:' increases fVIII RNA levels many times (Fig 1) argues against a mechanism that operates at the level of RNA stability. Furthermore, the suspected repressor element identified in this study functions independent of its orientation in a transcription unit, supporting a mechanism that operates at the DNA rather than the RNA level. Finally, the AH fragment encoding the A2 domain also markedly represses expression when placed upstream of the MuLV LTR that drives the CAT marker gene (F.J.F., S.J.C., and R.C.H., unpublished data, February 1994). Collectively, these data suggest that the repressor sequences act as a transcriptional silencer of expression.
It is still unclear whether the observed repression is of any physiologic relevance for the regulation of expression of the endogenous N I 1 1 in vivo. We cannot exclude the possibility that sequence elements that are normally separated by introns and, thus, are several kilobases apart are adjacent in the cDNA and by coincidence gain such a function. The 305-bp Xmn I-BgI I1 fragment is derived from exons 9 to I 1 of the W 1 1 1 gene and encompasses over 9 kb of genomic DNA.
The detailed mechanism by which the repressor acts is still unclear. The lack of transcription of the AI domain as observed by the absence of any hybridization signal with the fVIII-AI probe excludes transcriptional attenuation in the A2 domain as a mechanism. Such a mechanism has been found to regulate expression of the c-myc gene.'" The observation that repression can be relieved by cotransfection of excess amounts of competitor DNA implies that the repression is not caused by the DNA sequence itself (eg. a DNA conformation that is unfavorable to transcription), but rather suggests that cellular components play a role in the repression. Inspection of the sequence of the 305-bp fragment that is involved in the repression does not immediately reveal any overt consensus sites for binding of candidate repressors. To date, however, only a few higher eukaryotic repressor systems have been characterized in detail." In the 305-bp fragment, we did note two sequences with a 1011 1 match with the WTTTAYRTTTW consensus observed in 
